German biotech BioNTech is acquiring MAB Discovery’s operational antibody generation unit for an undisclosed amount.
The deal sees BioNTech acquire all assets, employees and propriety know-how for monoclonal antibody (mAb) generation from MAB Discovery.
However, the agreement allows MAB Discovery will retain ownership of (and all rights to) both its propriety preclinical development pipeline and its existing third-party service agreements.
The acquisition follows a successful collaboration between the companies that started over five years ago, in which antibodies have been generated with MAB Discovery’s proprietary technology that are currently being further developed by BioNTech.
“Having exclusive access to MAB Discovery’s finely-tuned proprietary know-how dramatically expands BioNTech’s targeting ligand repertoire and enables us to directly, rapidly and efficiently produce new mAb candidates,” said Dr. Ugur Sahin, CEO and Co-Founder of BioNTech.
“The technology will be utilised with our existing proprietary platforms including RiboMABS, a platform for generating a novel class of mRNA-encoded antibody drug candidates.”
The acquisition will be completed and the antibody generation unit transitioned at the end of the first quarter of 2019.